UroGen Pharma price target raised to $64 from $60 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on UroGen Pharma to $64 from $60 and keeps a Buy rating on the shares after the UGN-102 regulatory submission was accepted for review. The firm says UGN-102 could become the first FDA-approved medicine for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. It increased its probability of regulatory approval in the U.S. for the candidate to 90% from 85%.